Advertisement
ALT vs RCKT
Which Stock Would AI Choose? Altimmune (ALT) vs. Rocket Pharmaceuticals (RCKT) Stock Comparison
Key Takeaways
- Both ALT and RCKT are clinical-stage biopharmaceutical companies with no meaningful product revenue, making them highly sensitive to clinical data and regulatory catalysts.
- ALT (Altimmune) is advancing pemvidutide, a dual glucagon/GLP-1 receptor agonist, across metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
- RCKT (Rocket Pharmaceuticals) is a gene therapy developer focused on rare cardiovascular diseases, anchored by RP-A501 for Danon disease and the recently approved Kresladi for severe LAD-I.
- ALT has shown comparatively weaker recent price performance, while RCKT has benefited from an FDA alignment on its pivotal Danon disease trial and a strengthened balance sheet.
- Relative performance and market positioning diverge sharply: Altimmune carries a larger cash position but a longer timeline to pivotal data, whereas Rocket has a nearer-term launch (Kresladi) and a defined Phase 2 path.
- For more detail on each company's news and daily price action, explore the ALT Major News and ALT Today's Price Move pages, along with the RCKT Major News and RCKT Today's Price Move pages.
- For additional context on market signals, explore Trending AI Robots to see which strategies are currently favored by Tickeron's AI.
Introduction
Altimmune (ALT) and Rocket Pharmaceuticals (RCKT) both operate in biotechnology, yet they pursue fundamentally different therapeutic approaches and address different patient populations. This stock comparison is relevant for investors and traders evaluating clinical-stage drug developers whose share prices are driven primarily by pipeline milestones, regulatory decisions, and financing events rather than current earnings. While Altimmune is developing a peptide-based therapy for liver and metabolic conditions, Rocket is advancing one-time gene therapies for rare, often life-threatening diseases. Understanding the contrast in their growth drivers, risk profiles, and market positioning can help readers assess which story better aligns with their own objectives.
ALT Overview and Recent Performance
Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases. Its lead candidate, pemvidutide, is an investigational peptide with balanced 1:1 glucagon/GLP-1 receptor agonist activity (glucagon acts on the liver, while GLP-1 influences appetite and metabolism), being developed for MASH, AUD, and ALD. In recent months, the company has reported positive topline results from the Phase 2 RECLAIM study in AUD, initiated the global Phase 3 PERFORMA trial in MASH, and completed enrollment in the Phase 2 RESTORE study in ALD. Financially, Altimmune reported roughly $519 million in cash and investments as of mid-2026, which management expects to fund operations into 2029. Despite these advances, ALT shares have declined over the past year, reflecting investor caution about dilution from recent financings and a pivotal data readout not expected until 2029. Sentiment has been mixed, with clinical progress offset by the extended timeline to late-stage data.
RCKT Overview and Recent Performance
Rocket Pharmaceuticals is a fully integrated biotechnology company advancing gene therapies for rare and devastating cardiovascular diseases, with additional programs in hematology and immunology. Its most advanced candidate, RP-A501, is an investigational AAV-based gene therapy (adeno-associated virus, a delivery vehicle for genetic material) for Danon disease, a rare inherited disorder affecting the heart and other organs. In recent weeks, the company reached alignment with the U.S. Food and Drug Administration (FDA) on a pivotal Phase 2 study, a development that removed a significant regulatory overhang and prompted analyst upgrades. Rocket also secured access to up to $150 million through a credit facility with Hercules Capital and reported roughly $284 million in cash and investments as of mid-2026. Separately, its gene therapy Kresladi received accelerated FDA approval earlier in 2026 for severe leukocyte adhesion deficiency-I (LAD-I), with launch preparations underway. RCKT shares have risen modestly year to date, supported by regulatory progress and financing.
Trending AI Robots
For traders seeking a data-driven complement to fundamental analysis, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing automated strategies. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only the most suitable for current market conditions are featured in this section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker sets, allowing users to compare approaches across different risk profiles and holding periods. Because each robot is configured for specific market regimes, the trending selection provides a useful signal of which strategies are currently resonating. Readers interested in how algorithmic models are positioning in the current environment can explore the Trending AI Robots page to review the featured bots and their track records.
Head-to-Head Comparison
The two companies diverge across several key dimensions. In terms of business model, ALT is built around a single differentiated molecule applied across multiple liver and metabolic indications, whereas RCKT runs a platform of one-time gene therapies for rare, mostly cardiovascular diseases. Growth drivers also differ: Altimmune's value rests on pemvidutide's readouts across MASH, AUD, and ALD, while Rocket's hinges on RP-A501's pivotal Danon disease trial and the early commercialization of Kresladi. On momentum, RCKT has enjoyed a clearer near-term catalyst path following its FDA alignment and financing, whereas ALT faces a longer wait for Phase 3 data. Risk profiles contrast as well: Rocket carries execution risk around a single pivotal trial and a previously imposed clinical hold, while Altimmune contends with intense competition in the GLP-1 space and shareholder dilution. Sector exposure overlaps in healthcare but differs sharply in disease focus, patient size, and regulatory pathway. Market sentiment has favored Rocket's recent de-risking over Altimmune's longer-horizon pipeline, though both remain speculative, pre-revenue equities.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would currently lean toward RCKT over ALT. Rocket Pharmaceuticals has demonstrated a more favorable near-term trajectory, supported by an FDA-aligned pivotal trial, analyst upgrades, a strengthened balance sheet, and the initial commercialization of Kresladi. Altimmune's fundamentals and cash position are solid, but its most consequential catalyst is years away, and its recent relative performance has been softer. The AI's preference is probabilistic rather than definitive: it reflects the current weighting of catalysts and momentum, not a guaranteed outcome, and either stock could re-rate quickly on new clinical or regulatory developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and RCKT is a StrongBuy.
ALT's Indicator enters downward trend
The Aroon Indicator for ALT entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 278 similar instances where the Aroon Indicator formed such a pattern. In 249 of the 278 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for ALT crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ALT just turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (3.104). P/E Ratio (-2.658) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1728.730) settles around the average of (129.907) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.647).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 32 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RCKT as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +13.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 203 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.735) is normal, around the industry mean (3.104). P/E Ratio (-15.438) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALT | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 92 | |
PRICE GROWTH RATING 1..100 | 83 | 76 | |
P/E GROWTH RATING 1..100 | 17 | 17 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (11) in the Biotechnology industry is significantly better than the same rating for ALT (94) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew significantly faster than ALT’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as ALT (96) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.
RCKT's Price Growth Rating (76) in the Biotechnology industry is in the same range as ALT (83) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.
RCKT's P/E Growth Rating (17) in the Biotechnology industry is in the same range as ALT (17) in the Miscellaneous Commercial Services industry. This means that RCKT’s stock grew similarly to ALT’s over the last 12 months.
| ALT | RCKT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Stochastic ODDS (%) | N/A | 2 days ago 83% |
| Momentum ODDS (%) | N/A | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| Advances ODDS (%) | 6 days ago 79% | 7 days ago 80% |
| Declines ODDS (%) | 2 days ago 88% | 5 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALT’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- ALT’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALT’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).
- ALT’s TA Score: 4 bullish, 3 bearish.
- RCKT’s TA Score: 5 bullish, 3 bearish.
Price Growth
ALT (@Biotechnology) experienced а -1.46% price change this week, while RCKT (@Biotechnology) price change was +8.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.94%. For the same industry, the average monthly price growth was -11.98%, and the average quarterly price growth was -17.06%.
Reported Earning Dates
ALT is expected to report earnings on Nov 05, 2026.
RCKT is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.
| Ticker / NAME | Correlation To ALT | 1D Price Change % | ||
|---|---|---|---|---|
| ALT | 100% | -0.98% | ||
| OGEN - ALT | 54% Loosely correlated | -1.02% | ||
| INDP - ALT | 45% Loosely correlated | +13.27% | ||
| FLNA - ALT | 45% Loosely correlated | -9.81% | ||
| EDIT - ALT | 43% Loosely correlated | -3.75% | ||
| DNLI - ALT | 43% Loosely correlated | -0.42% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BNOV | 48.45 | -0.14 | -0.29% |
| Innovator U.S. Equity Buffer ETF - November (BNOV) | |||
| EUSB | 42.19 | -0.13 | -0.31% |
| iShares ESG Advanced Universal USD Bond ETF (EUSB) | |||
| SPIB | 32.53 | -0.14 | -0.43% |
| State Street SPDR Portfolio Intermediate Term Corporate Bond ETF (SPIB) | |||
| QVOY | 27.69 | -0.40 | -1.42% |
| Q3 All-Season Active Rotation ETF (QVOY) | |||
| OILT | 33.70 | -1.73 | -4.87% |
| Texas Capital Texas Oil Index ETF (OILT) | |||